Matches in Wikidata for { <http://www.wikidata.org/entity/Q37723277> ?p ?o ?g. }
- Q37723277 description "article científic" @default.
- Q37723277 description "article scientifique" @default.
- Q37723277 description "articolo scientifico" @default.
- Q37723277 description "artigo científico" @default.
- Q37723277 description "artículu científicu espublizáu en 2013" @default.
- Q37723277 description "bilimsel makale" @default.
- Q37723277 description "scientific article published on 26 September 2013" @default.
- Q37723277 description "vedecký článok" @default.
- Q37723277 description "vetenskaplig artikel" @default.
- Q37723277 description "videnskabelig artikel" @default.
- Q37723277 description "vědecký článek" @default.
- Q37723277 description "wetenschappelijk artikel" @default.
- Q37723277 description "wissenschaftlicher Artikel" @default.
- Q37723277 description "наукова стаття, опублікована у вересні 2013" @default.
- Q37723277 description "научни чланак" @default.
- Q37723277 description "مقالة علمية نشرت في 26 سبتمبر 2013" @default.
- Q37723277 name "Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma" @default.
- Q37723277 name "Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma" @default.
- Q37723277 name "Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma" @default.
- Q37723277 type Item @default.
- Q37723277 label "Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma" @default.
- Q37723277 label "Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma" @default.
- Q37723277 label "Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma" @default.
- Q37723277 prefLabel "Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma" @default.
- Q37723277 prefLabel "Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma" @default.
- Q37723277 prefLabel "Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma" @default.
- Q37723277 P1433 Q37723277-34FF5D20-E265-4BB1-A1BA-E755E2654D08 @default.
- Q37723277 P1476 Q37723277-E670E0D7-925D-4C59-B434-1CDAB22F2A42 @default.
- Q37723277 P2093 Q37723277-119A8020-1DE2-4324-B613-C89777E33405 @default.
- Q37723277 P2093 Q37723277-17C13705-D904-489C-9516-A91868C710ED @default.
- Q37723277 P2093 Q37723277-6777CE13-73F7-49D6-B306-4799D9532483 @default.
- Q37723277 P2093 Q37723277-6AFC8327-8288-4DE0-9F5A-64BECCDCAAA0 @default.
- Q37723277 P2093 Q37723277-8B698089-1205-44DF-9FDC-E09BF24BEBB2 @default.
- Q37723277 P2093 Q37723277-B090F8C7-6D32-4B7B-BB62-CD9FFEAD8737 @default.
- Q37723277 P2093 Q37723277-BA9CE9A2-CC7B-45B9-B327-7E1457C7A788 @default.
- Q37723277 P2093 Q37723277-BBEE13E7-CBDA-44DD-BA54-4A019983113C @default.
- Q37723277 P2093 Q37723277-BD4AD315-B42C-49B1-AA79-A438F0952BCE @default.
- Q37723277 P2093 Q37723277-BFBC3327-BE0B-4CC2-9DF1-94E4D6828680 @default.
- Q37723277 P2093 Q37723277-CDD40505-9094-4D1E-8F50-4585878C7F79 @default.
- Q37723277 P2093 Q37723277-F8DD7BBF-1BB9-40B9-BB8C-659EDBD656AF @default.
- Q37723277 P2860 Q37723277-008D2850-4DED-4BC3-9B75-B61E736E8FC8 @default.
- Q37723277 P2860 Q37723277-067910A7-3BC8-432B-BB54-1B52036DFBA5 @default.
- Q37723277 P2860 Q37723277-0B48EE02-6847-466C-B9EA-402B40B07F02 @default.
- Q37723277 P2860 Q37723277-2250CB85-66B8-4773-9BCE-EA464270EA5C @default.
- Q37723277 P2860 Q37723277-39122066-0150-46B2-AFC9-AA28801F5F23 @default.
- Q37723277 P2860 Q37723277-398E1335-94E6-41C6-A412-69AC9D44B0B1 @default.
- Q37723277 P2860 Q37723277-3F7323BF-423F-43E7-83BD-7DCACECC1543 @default.
- Q37723277 P2860 Q37723277-4227FF12-F284-472D-84D2-E3A4A8006148 @default.
- Q37723277 P2860 Q37723277-45A41C9D-660B-4FDC-86C0-9FCA7EA061FE @default.
- Q37723277 P2860 Q37723277-4BAD530A-720C-4E1B-ACA0-EE2331B277FD @default.
- Q37723277 P2860 Q37723277-53ADD5D1-262A-463C-8299-038552A1BF87 @default.
- Q37723277 P2860 Q37723277-56AC6BB5-C422-412F-9B37-01960B2ED85F @default.
- Q37723277 P2860 Q37723277-6063AE12-DAAA-4A1C-A084-980D5AE25C6A @default.
- Q37723277 P2860 Q37723277-66ECF1DF-D54C-42BB-8B2B-7DCD2A884454 @default.
- Q37723277 P2860 Q37723277-705CA228-BCAE-4708-ADCE-78B5A380C402 @default.
- Q37723277 P2860 Q37723277-819518A9-E25A-46CF-B33E-72FFA8F676EA @default.
- Q37723277 P2860 Q37723277-95465457-520F-4F70-8D63-05A40865C8A3 @default.
- Q37723277 P2860 Q37723277-99C80C3B-C486-4F6B-89E1-FBA80E97C3A1 @default.
- Q37723277 P2860 Q37723277-9B2CB3D6-B2E3-4CFF-9C35-D6128EE97CDA @default.
- Q37723277 P2860 Q37723277-9F88F651-B053-4519-A56F-AC34C5C8AE76 @default.
- Q37723277 P2860 Q37723277-9FC37FE6-5287-4C60-9115-9BB96D602216 @default.
- Q37723277 P2860 Q37723277-A709E65D-28B6-49DA-AC75-910B653557A5 @default.
- Q37723277 P2860 Q37723277-A84269E1-3F0D-44AB-8A7F-E3450D30AC88 @default.
- Q37723277 P2860 Q37723277-A96D024A-72BB-45E2-A45A-309591E48323 @default.
- Q37723277 P2860 Q37723277-AAC67A4A-8116-4E23-A9A5-3760A3FD5F2D @default.
- Q37723277 P2860 Q37723277-ACF22D41-5C42-47FE-9068-EE90640E41CC @default.
- Q37723277 P2860 Q37723277-AF55388D-5A6A-4093-A4F5-6ECE8A5FF645 @default.
- Q37723277 P2860 Q37723277-AF842723-D714-47C0-AC63-92EFFA33F719 @default.
- Q37723277 P2860 Q37723277-B75EE71F-6856-4294-BCDA-4026A344F262 @default.
- Q37723277 P2860 Q37723277-C1F828DD-6E9F-41A3-ADD5-0C33E9E7E133 @default.
- Q37723277 P2860 Q37723277-C596A066-E0D8-4EF6-B9E0-B95158867945 @default.
- Q37723277 P2860 Q37723277-D79F4FC0-7940-40CB-AFF7-D9CBDBB4947F @default.
- Q37723277 P2860 Q37723277-D9705426-7F3A-4420-AAD5-27EE4B95DAAD @default.
- Q37723277 P2860 Q37723277-DBBB77AB-F140-4D9A-BE62-FD134CBB4730 @default.
- Q37723277 P2860 Q37723277-E0CDD2FF-6B12-4D2C-A802-C60EF0E92A93 @default.
- Q37723277 P2860 Q37723277-E98ED06B-6E01-49C2-AE94-9AE9382633CF @default.
- Q37723277 P2860 Q37723277-EC37ADC1-BE05-44A9-8E30-F861AF90930B @default.
- Q37723277 P2860 Q37723277-ED6F051A-531D-448C-AFC6-852A1B18D52A @default.
- Q37723277 P2860 Q37723277-F92F29F0-1DE6-4016-8229-26CDD3C04D13 @default.
- Q37723277 P2888 Q37723277-789122FB-7858-4509-ABD2-B692B00426FA @default.
- Q37723277 P304 Q37723277-DECA94AD-45C0-4692-A78B-1043B17BBC48 @default.
- Q37723277 P31 Q37723277-4D3EA556-03A7-42DA-99A3-E11F564F6DC9 @default.
- Q37723277 P356 Q37723277-1530B75A-14E4-4748-BD5F-D67A3B2471C5 @default.
- Q37723277 P407 Q37723277-00CD1B46-75C1-4EE0-8111-B572BD79689F @default.
- Q37723277 P433 Q37723277-673CC09A-4776-4CBA-95FA-F050BD3D5FA6 @default.
- Q37723277 P478 Q37723277-D38C7AF3-3033-4C06-A732-974F158BC17C @default.
- Q37723277 P50 Q37723277-39564B17-F0A6-4F60-941F-B9596442FC51 @default.
- Q37723277 P50 Q37723277-56BA2C49-B6CE-476F-B800-5C66A5FC879A @default.
- Q37723277 P577 Q37723277-EFC3998A-9FEB-4412-821B-F1534B95F18A @default.
- Q37723277 P698 Q37723277-37C14A47-C0F4-4E2B-8ED1-A950F983ECB5 @default.
- Q37723277 P921 Q37723277-5294310A-C7DC-4F0F-9D99-BFF76C94A222 @default.
- Q37723277 P921 Q37723277-552812B7-31E9-4388-AF4C-3499E0199FF4 @default.
- Q37723277 P932 Q37723277-129AFD9D-89B5-4648-B489-1A098784CE40 @default.
- Q37723277 P356 S10549-013-2704-X @default.
- Q37723277 P698 24068539 @default.
- Q37723277 P1433 Q326085 @default.
- Q37723277 P1476 "Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma" @default.
- Q37723277 P2093 "Christine M Pellegrino" @default.
- Q37723277 P2093 "Dawn L Hershman" @default.
- Q37723277 P2093 "Eleni Andreopoulou" @default.